Group 1: Company Developments - The company has received FDA approval for its innovative drug SIR-Spheres® for treating unresectable hepatocellular carcinoma (HCC) [1] - The company’s nasal spray product OC-01 for dry eye syndrome has been approved in mainland China and has begun commercial prescriptions [1][3] - OC-01 is the only nasal spray approved for treating dry eye syndrome in China, providing a new treatment option for patients [1] Group 2: Market Insights - The dry eye syndrome market in China is estimated to have around 360 million patients, with a prevalence rate of approximately 21.0% to 52.4% [3] - The overall dry eye syndrome market in China has a compound annual growth rate (CAGR) of 1.6% from 2017 to 2021, with moderate growth expected in the coming years [4] - The global dry eye syndrome market is projected to reach $25.48 billion in 2024, expanding at a CAGR of 3.4% to $33.26 billion by 2033 [6] Group 3: Product Advantages - OC-01 utilizes a nasal delivery method that enhances tear secretion and improves tear film stability, potentially increasing patient compliance compared to traditional eye drops [7] - The product has shown strong commercial potential, with over 97,000 prescriptions in the U.S. within its first year and approximately $42 million in sales revenue in 2023 [7] - The company has a comprehensive pipeline of innovative ophthalmic products, including treatments for various eye conditions, which are expected to contribute to future revenue growth [11][14] Group 4: Competitive Landscape - The ophthalmic drug market in China has grown from 15.1 billion RMB in 2016 to 18.8 billion RMB in 2020, with a projected market size of 44 billion RMB by 2025 [8] - The company is strategically positioned in the competitive ophthalmic market, focusing on innovative product development to maintain its leading position [10] - The company has established a professional marketing team and a nationwide distribution network to support its ophthalmic product sales [14]
远大医药（00512）创新眼药OC-01首张处方落地 开启鼻喷雾剂治疗干眼新纪元